4DMedical Limited
4DX.AXHealthcareASXMedical Devices
Scan Results
Daily timeframe4DMedical Limited operates as a medical technology company in the United States and Australia. The company carries a $2.35B market cap, placing it firmly in the mid-cap category. The company engages in the medical research technology and development of a non-invasive respiratory imaging solution using four-dimensional imaging.
Market Cap
$2.35B
Beta
1.97
P/E (TTM)
—
P/E (Fwd)
-106.23
EPS (TTM)
$-0.40
EPS (Fwd)
$-0.04
ROE
-1099.3%
ROA
-26.1%
Cash
$56.8M
Total Debt
$10.2M
Free CF
-$117.5M
52W Change
1160.3%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $56.8M in cash comfortably exceeding the $10.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$117.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -1099.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $1.1M (2022) to $5.8M (2025), reflecting a 448% increase over the period.
With a beta above 1.5, 4DX.AX tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing 4DX.AX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.